In this report, we evaluate a treatment regimen of paclitaxel, ganitumab, and metformin (PGM) compared to paclitaxel alone in HER2-negative operable breast cancer in the I-SPY2 trial. The gene discussed is ERBB2; the disease is breast cancer.